EY: Post-boom biotech still has plenty of upbeat trends to boast about
If you just compare the top-line biotech numbers for 2016 to 2015, you’d have good reason to despair. New drug approvals by the FDA plunged …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
